Skip to main content
. 2018 Apr 15;8(10):2846–2861. doi: 10.7150/thno.23463

Figure 1.

Figure 1

TGF-β upregulates UCA1 and AC026904.1 through Smad and ERK signaling, respectively. (A) Phase-contrast images of MCF7 cells treated with TGF-β1 (10 ng/mL) or control vehicle for 4 days. Scale bar: 50 μm. (B) Relative mRNA levels of EMT markers (mean ± SEM, n = 3) in MCF7 cells treated with TGF-β1 (10 ng/mL) for 4 days. (C) Left panel: Scatter plot of microarray analysis of differentially expressed lncRNAs in TGF-β1 treated and untreated cells. Right panel: Top upregulated lncRNAs in TGF-β-treated MCF7 cells. (D) Relative RNA levels of AC026904.1 and UCA1 (mean ± SEM, n = 3) in MCF7 or MDA-MB-231 cells treated with TGF-β1. (E) Confocal RNA-FISH images showing subcellular localization of UCA1 and AC026904.1 in MCF7 cells underwent EMT. Scale bar: 10μm. (F) Relative RNA levels of AC026904.1 and UCA1 (mean ± SEM, n = 3) in cytoplasmic or nuclear RNA fraction of MCF7 cells treated with TGF-β1. (G) Relative RNA levels of AC026904.1 and UCA1 (mean ± SEM, n = 3) in MDA-MB-231 cells pretreated with SB431542 (10 μM) for 60 min, followed by TGF-β1 for 24 h. (H) Relative RNA levels of AC026904.1 (mean ± SEM, n = 3) in MDA-MB-231 cells pretreated with MK-2206 or U0126 or SP600125 or SB203580, followed by TGF-β1 for 24 h. (I) Relative RNA levels of AC026904.1 and UCA1 (mean ± SEM, n = 3) in MDA-MB-231 cells pretreated with si-Control or si-Smad3 or si-ERK2, followed by TGF-β1 for 24 h.